BioCryst Pharmaceuticals
BCRXApprovedFounded in 1986, BioCryst Pharmaceuticals is a global, commercial-stage biotech company headquartered in Durham, North Carolina, focused on discovering and developing novel treatments for rare diseases. Its core expertise lies in structure-guided drug design, which it uses to create highly selective oral and injectable therapies. The company has successfully commercialized ORLADEYO for HAE and is advancing a pipeline of investigational candidates, including navenibart for HAE and BCX17725 for Netherton syndrome, while also marketing RAPIVAB for influenza.
BCRX · Stock Price
Historical price data
AI Company Overview
Founded in 1986, BioCryst Pharmaceuticals is a global, commercial-stage biotech company headquartered in Durham, North Carolina, focused on discovering and developing novel treatments for rare diseases. Its core expertise lies in structure-guided drug design, which it uses to create highly selective oral and injectable therapies. The company has successfully commercialized ORLADEYO for HAE and is advancing a pipeline of investigational candidates, including navenibart for HAE and BCX17725 for Netherton syndrome, while also marketing RAPIVAB for influenza.
Technology Platform
Structure-guided drug design platform that uses X-ray crystallography, cryo-EM, and computational modeling to design oral small-molecule and protein therapeutics atom-by-atom to fit specific protein active sites.
Pipeline Snapshot
5555 drugs in pipeline, 15 in Phase 3
| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Peramivir + Peramivir | Seasonal Influenza | Phase 3 | |
| berotralstat | Hereditary Angioedema | Phase 3 | |
| Peramivir + Placebo | Influenza | Phase 3 | |
| BCX7353 capsules + Placebo oral capsule | Hereditary Angioedema | Phase 3 | |
| Peramivir + Placebo Comparator | Influenza | Phase 3 |
Funding History
2Total raised: $100M
FDA Approved Drugs
3Opportunities
Risk Factors
Competitive Landscape
In HAE, BioCryst competes with Takeda (Takhzyro), CSL Behring (Haegarda, Cinryze), and Pharvaris (oral candidate). ORLADEYO's key differentiation is its oral, once-daily dosing. For pipeline candidates, competition includes other biologics in HAE and, potentially, other developers targeting Netherton syndrome.
Company Info
Trading
Contact
Therapeutic Areas
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile